ACC.26 Signals a New Era in Cardiovascular Care

The message from this year’s American College of Cardiology 75th Annual Scientific Session & Expo (ACC.26, New Orleans, LA, USA, March 28-30 2026) was unmistakable: cardiovascular medicine is entering an era defined not only by precision therapeutics and structural innovation, but by increasingly ambitious efforts to intervene earlier, individualize care and reduce lifelong treatment burden.

ACC.26 brought together thousands of clinicians, researchers and industry leaders for three days of late-breaking science, guideline-focused education and translational debate. With more than 300 educational sessions, over 1,300 faculty speakers and 60 late-breaking clinical studies, the congress underscored the accelerating pace of change across interventional cardiology, preventive medicine, heart failure and electrophysiology.¹

Among the most closely watched presentations was CHAMPION-AF (NCT04394546), which revisited the role of left atrial appendage closure (LAAC) as an alternative to long-term oral anticoagulation in patients with atrial fibrillation. Investigators presented primary outcomes comparing device-based LAAC with standard anticoagulation therapy, adding fresh momentum to an area that has generated considerable debate in recent years.²

Acute coronary care also featured prominently. The STEMI-Door to Unload (STEMI-DTU; NCT03947619) trial evaluated whether primary left ventricular unloading before reperfusion could improve outcomes in anterior ST-elevation myocardial infarction without cardiogenic shock. Mechanical unloading strategies have attracted growing interest over the past decade, and the ACC.26 data provided important insight into whether modifying myocardial stress before percutaneous coronary intervention (PCI) can alter infarct progression and clinical outcomes.³

Interventional cardiology sessions were rich in imaging- and physiology-guided PCI data. Trials including IVUS-CHIP (NCT04854070), DKCRUSH VIII (NCT03770650) and OPTIMAL (NCT04111770) explored intravascular imaging, bifurcation intervention and left main disease management, reinforcing the trend toward increasingly tailored procedural strategies. ORBITA-CTO (NCT05142215) and FAST III (NCT04931771) also revisited the balance between anatomy-guided and physiology-guided revascularization approaches.³

Prevention and lipid management emerged as another major theme. Results from VESALIUS-CV (NCT03872401) examined evolocumab use in patients without clinically established atherosclerotic cardiovascular disease (ASCVD), potentially broadening discussions around earlier preventive intervention. Additional studies presented intensive low-density lipoprotein (LDL)-cholesterol lowering data in patients with established ASCVD, while sessions on dyslipidaemia management and cardiovascular risk prediction reflected continued interest in refining primary prevention pathways.¹

Heart failure specialists also had significant new data to consider. Late-breaking presentations included updated evidence on spironolactone use across heart failure populations, alongside device and monitoring strategies designed to improve outpatient management and congestion detection. Structural heart disease remained another focal point of the meeting, particularly with the SURVIV trial comparing redo surgery versus transcatheter valve-in-valve therapy for mitral bioprosthetic dysfunction — an increasingly relevant issue as transcatheter interventions continue to expand into lower-risk and younger populations.¹

Digital medicine and artificial intelligence featured heavily throughout the programme. Sessions explored artificial intelligence (AI)-assisted imaging interpretation, surgical assessment and risk prediction, reflecting the growing integration of computational tools into routine cardiovascular care. Alongside the enthusiasm, speakers repeatedly emphasized the need for careful implementation, robust validation and clinician oversight as these technologies move closer to mainstream practice.¹

The congress also highlighted conditions that have historically received less attention in mainstream cardiology discussions. Sessions focusing on ischemia with nonobstructive coronary arteries (INOCA), sex-specific cardiovascular mechanisms and pulmonary embolism management reflected broader efforts to address persistent gaps in evidence and patient care. The HI-PEITHO trial (NCT04790370), evaluating catheter-directed thrombolysis in intermediate-high-risk pulmonary embolism (PE), added further data to ongoing discussions around more selective interventional approaches in PE management.¹

Taken together, ACC.26 reflected a specialty increasingly focused on prevention, personalization and earlier intervention across the cardiovascular continuum. Many of the studies presented are likely to influence clinical practice and future guideline discussions, while others will continue to fuel debate around patient selection, implementation and long-term value.

Further expert analysis and faculty interviews from ACC.26 are available here at touchCARDIO.com, where investigators discuss the clinical implications behind the meeting’s most important late-breaking trials and emerging data.